7.2.3　Sorafenib（Sorafenib，BAY43-9006）

Sorafenib is a multi-targeted serine/threonine kinase inhibitor with targets including c-raf and b-raf as well as RET，Flt-3 and c-kit.Sorafenib also has strong activity in tyrosine kinases，including the VEGFR family（VEGFR1～3）and platelet-derived growth factor receptor（PDGFR），which are important receptors in tumor angiogenesis.Therefore，the anti-tumor activity of sorafenib in the body is directly inhibited by the Raf/MEK/ERK pathway on tumor growth；the second is through the anti-angiogenic effect of the drug.For the treatment of metastatic renal clear cell carcinoma，advanced liver cancer and thyroid cancer.(https://www.daowen.com)

The single-agent sorafenib did not show strong activity in metastatic breast cancer.The solitif-0701 phase Ⅱ clinical trial evaluated the efficacy of sorafenib in combination with capecitabine in the progression or metastatic triple-negative breast cancer.229 patients were enrolled.The results showed that although there was no difference in OS，the median PFS（6.4 months vs 4.1 months，p=0.001）and ORR（38%vs 31%，p=0.25）increased and good tolerance，Adverse reactions such as rash，diarrhea，mucositis，neutropenia，hand-foot syndrome，etc.Resilifence phase Ⅲ clinical studies have shown that sorafenib can not prolong the PFS and OS of HER-2 negative breast cancer patients.